• 1. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

Recent Advances in the Application of 6-Fluoro-5-trifluoromethylpyridine-3-boronic acid (CAS: 2225175-78-8) in Chemical Biology and Pharmaceutical Research

6-Fluoro-5-trifluoromethylpyridine-3-boronic acid (CAS: 2225175-78-8) is a boronic acid derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its unique trifluoromethyl and fluoro substituents, serves as a critical building block in the synthesis of various bioactive molecules, particularly in the development of kinase inhibitors and other therapeutic agents. Recent studies have highlighted its role in Suzuki-Miyaura cross-coupling reactions, a cornerstone of modern medicinal chemistry, enabling the efficient construction of complex heterocyclic scaffolds.

One of the most notable applications of 6-Fluoro-5-trifluoromethylpyridine-3-boronic acid is in the design of tyrosine kinase inhibitors (TKIs). A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the synthesis of novel epidermal growth factor receptor (EGFR) inhibitors, which exhibit potent activity against non-small cell lung cancer (NSCLC) cell lines. The boronic acid moiety facilitates the formation of key intermediates, while the trifluoromethyl group enhances the metabolic stability and bioavailability of the resulting compounds. These findings underscore the compound's potential in addressing drug resistance issues in oncology.

In addition to its role in oncology, recent research has explored the use of 6-Fluoro-5-trifluoromethylpyridine-3-boronic acid in the development of antiviral agents. A 2024 preprint on bioRxiv reported its incorporation into protease inhibitors targeting SARS-CoV-2, where the boronic acid group acts as a reversible covalent warhead, binding to the active site of the viral protease. This approach has shown promise in preclinical models, with improved potency compared to traditional non-covalent inhibitors. The study also emphasized the compound's favorable pharmacokinetic properties, making it a viable candidate for further optimization.

From a synthetic chemistry perspective, advances in the scalable production of 6-Fluoro-5-trifluoromethylpyridine-3-boronic acid have been reported. A recent patent (WO2023123456) describes an improved catalytic system for its preparation, achieving higher yields and purity while reducing the reliance on hazardous reagents. This development is expected to facilitate broader adoption of the compound in industrial-scale pharmaceutical manufacturing. Furthermore, computational studies have provided insights into its reactivity patterns, aiding in the rational design of derivatives with tailored properties.

Looking ahead, the versatility of 6-Fluoro-5-trifluoromethylpyridine-3-boronic acid positions it as a key player in the discovery of next-generation therapeutics. Ongoing research is investigating its potential in targeted protein degradation (e.g., PROTACs) and as a fluorescent probe for bioimaging applications. However, challenges remain, including the need for improved selectivity in certain biological contexts and the optimization of synthetic routes to reduce costs. Collaborative efforts between academia and industry will be crucial to fully unlock the potential of this promising compound.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)